TADA2B

TADA2B Full Name

transcriptional adaptor 2B

TADA2B Introduction

Transcriptional Adaptor 2B (TADA2B), is a protein-coding gene located on human chromosome 4p16.1 that spans approximately 14.6 kilobases and contains two coding exons. The TADA2B gene produces a 420-amino acid protein that functions primarily as a transcriptional adaptor—a molecular bridge that facilitates communication between sequence-specific transcription factors and the basal transcription machinery. TADA2B achieves this by coordinating histone acetyltransferase (HAT) activity and linking activation factors to the core transcriptional apparatus. The protein is evolutionarily conserved from yeast to humans, with human TADA2B sharing 100% amino acid identity with its mouse ortholog and 59% similarity with the closely related human TADA2A, indicating that its fundamental role in gene regulation has been preserved throughout eukaryotic evolution.

Figure 1. Transcriptional adaptor 2b in gene activation.

Structural Domains of TADA2B
The TADA2B protein is built around two evolutionarily conserved structural modules that enable its molecular functions. It contains a SANT (Swi3, Ada2, N-CoR, and TFIIIB) domain, which serves as a versatile protein-protein interaction module that allows TADA2B to engage with multiple binding partners within transcription-regulating complexes. In addition, TADA2B possesses a ZZ-type zinc finger, a specialized protein/DNA-binding motif that contributes to chromatin interactions and transcriptional regulation. Zinc-finger proteins are characterized by DNA-binding domains that typically mediate transcriptional activation or repression, and the ZZ-type zinc finger in TADA2B is specifically found in ADA2-like proteins across animals and plants, highlighting its functional importance in the ADA2 family. Together, these domains enable TADA2B to function as a molecular hub that coordinates both protein-protein and protein-DNA interactions within the nucleus.

Emerging Roles in Cancer and Therapeutic Implications
Recent research has revealed that TADA2B plays a significant role in cancer biology, particularly in transcriptionally driven pediatric malignancies. In MYCN-amplified neuroblastoma—a high-risk childhood cancer driven by aberrant oncogenic transcription—the KAT module of the SAGA complex, which includes TADA2B, was identified as a selective dependency. Loss of SAGA complex activity through genetic knockout or induced degradation of TADA2B led to a global reduction of histone lysine acetylation, impaired neuroblastoma cell growth, and reduced MYCN binding to chromatin, suppressing the oncogenic gene expression program. Notably, TADA2B knockout did not impair the growth of pediatric sarcoma cell lines, suggesting that SAGA loss-of-function is not universally deleterious and may offer a therapeutic window for targeting MYCN-amplified tumors. The SAGA complex is pharmacologically targetable using PROTACs such as GSK-699 that induce proteolysis of KAT2A and KAT2B, and the suppression of SAGA activity has been shown to reduce the MYCN-driven transcriptional signature and impair cell cycle progression. These findings position TADA2B and the SAGA KAT module as promising therapeutic targets for transcriptionally addicted cancers.

Alternate Names for TADA2B

TADA2B; transcriptional adaptor 2B; ADA2B; ADA2(beta); transcriptional adapter 2-beta; ADA2-beta; ADA2-like protein beta; transcriptional adaptor 2 (ADA2 homolog, yeast)-beta;